The first 60 days: Imatinib-resistant GIST
Imatinib-resistant GIST is disease that has grown through the first drug, usually because the tumour has acquired a second KIT mutation that imatinib cannot block. Sunitinib, regorafenib and ripretinib are given in turn; ripretinib, in the INVICTUS trial, extended progression-free survival from 1 to 6 months in patients who had exhausted the other three. Below, week by week, is what OnCo's record of Imatinib-resistant GIST says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Second line.
- SurgeonNamed in the standard of care for: Progression on imatinib 400 mg.
- Medical oncologistNamed in the standard of care for: Progression on imatinib 400 mg, Second line, Third line, Fourth line and beyond.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Confirm adherence and plasma level; dose escalation to 800 mg (especially exon 9); local therapy for isolated progression while continuing imatinib.
Sunitinib; ripretinib as an alternative, preferred where the secondary mutation is in exon 17 or 18 (INTRIGUE subgroup; INSIGHT ongoing).
Regorafenib (GRID).
Ripretinib (INVICTUS); imatinib rechallenge; trials of next-generation KIT inhibitors.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Secondary KIT mutations by circulating tumour DNA, Primary KIT or PDGFRA mutation, Growth within a treated lesion on CT, Imatinib plasma level to exclude underdosing, Thyroid function and blood pressure on sunitinib and regorafenib), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include GIST with KIT exon 13 or 14 secondary mutation, GIST with KIT exon 17 or 18 secondary mutation, Polyclonal resistance with multiple secondary KIT mutations.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Progression on imatinib 400 mg
- For my situation (progression on imatinib 400 mg), which of the standard options do you recommend and why?Guideline options include: Confirm adherence and plasma level; dose escalation to 800 mg (especially exon 9); local therapy for isolated progression while continuing imatinib.
- Am I a candidate for Imatinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Second line
- For my situation (second line), which of the standard options do you recommend and why?Guideline options include: Sunitinib; ripretinib as an alternative, preferred where the secondary mutation is in exon 17 or 18 (INTRIGUE subgroup; INSIGHT ongoing).
- Am I a candidate for Sunitinib, Ripretinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib and INSIGHT apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Third line
- For my situation (third line), which of the standard options do you recommend and why?Guideline options include: Regorafenib (GRID).
- Am I a candidate for Regorafenib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Fourth line and beyond
- For my situation (fourth line and beyond), which of the standard options do you recommend and why?Guideline options include: Ripretinib (INVICTUS); imatinib rechallenge; trials of next-generation KIT inhibitors.
- Am I a candidate for Ripretinib, Imatinib, IDRX-42 or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of INVICTUS apply to someone like me?Trial populations differ from individual patients; ask how closely you match.
Any stage
- Are there clinical trials I could join, for example of INSIGHT, IDRX-42, NB003, Bezuclastinib?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Polyclonal resistance means no single inhibitor covers every metastasis”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Each later line adds months, not years, and toxicity accumulates”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With ImatinibPhase 3 · active · NCT03673501A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of Ripretinib vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) After Treatment With Imatinib
- INSIGHTPhase 3 · active · NCT05734105Second-line GIST with KIT exon 11 + exon 17/18 mutations (ctDNA-selected): ripretinib vs sunitinib
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- Imatinib-resistant GIST: the full pageImatinib-resistant GIST is disease that has grown through the first drug, usually because the tumour has acquired a second KIT mutation that imatinib cannot block. Sunitinib, regorafenib and ripretinib are given in turn; ripretinib, in the INVICTUS trial, extended progression-free survival from 1 to 6 months in patients who had exhausted the other three.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.